Industrial Transformation Training Centres - Grant ID: IC160100027
Funder
Australian Research Council
Funding Amount
$4,340,802.00
Summary
ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. Ne ....ARC Training Centre for Biopharmaceutical Innovation. ARC Training Centre for Biopharmaceutical Innovation. This centre aims to transform Australia’s growing biopharmaceutical industry, an advanced manufacturing capability, by training specialist biotechnologists and bioengineers. It expects the research and development outputs will create new biopharmaceuticals and antibody-based reagents, enhanced production methods, improved manufacturing capabilities and a cohort of specialist scientists. New biopharmaceuticals are expected to benefit the Australian economy and provide new therapeutic options for better health outcomes. Industry-driven research projects will also provide industry-ready graduates who can drive future growth in the sector.Read moreRead less
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less
The first integrated multimodal assay for the ultrasensitive detection of dengue contamination of blood. This project will develop the first screening test to check for dengue contamination of blood donations in Australia. This will help ensure safe, continued supply from blood donors, particularly in Queensland where dengue is on the rise.
Discovery Early Career Researcher Award - Grant ID: DE190100174
Funder
Australian Research Council
Funding Amount
$400,747.00
Summary
Calcium-mediated regulation of stem cell development. This project aims to clarify the role of syndecan-mediated calcium in stem cell development using Caenorhabditis elegans. Stem cells have great potential for regenerative studies. While stem cells cultures are widely used, we do not fully understand how stem cells develop within an organism. This project expects to uncover the mechanisms underpinning calcium regulation by syndecan in stem cells. The expected outcomes include the optimisation ....Calcium-mediated regulation of stem cell development. This project aims to clarify the role of syndecan-mediated calcium in stem cell development using Caenorhabditis elegans. Stem cells have great potential for regenerative studies. While stem cells cultures are widely used, we do not fully understand how stem cells develop within an organism. This project expects to uncover the mechanisms underpinning calcium regulation by syndecan in stem cells. The expected outcomes include the optimisation of C. elegans stem cell methods to screen calcium regulating compounds and the creation of an in vivo calcium sensor. The project should advance knowledge of the role of syndecans in stem cells and provide the first analysis of in vivo calcium kinetics in stem cells.Read moreRead less
Intracellular trafficking and function of a recycling receptor which prolongs the serum half-life of novel therapeutic proteins. The life span of recombinant engineered proteins for therapeutic use is a critical factor in their effectiveness, ease of clinical application and cost. This project will exploit interactions with a natural receptor, which prolongs the lifespan of serum proteins, to enhance survival of therapeutic engineered proteins.